This seminar focuses on the corporate-governance implications of AI-specifically the fiduciary duties of boards in overseeing AI strategy and risk. It applies the duty of care and the business-judgment rule to AI adoption and emphasizes the duty of loyalty and good-faith oversight.
It then analyzes the Caremark standard in depth, applying the doctrine of board oversight of mission-critical risks to algorithmic bias, data privacy, and cybersecurity, and highlights the risk of personal director liability for systematic oversight failures. The program addresses how to structure board oversight-specialized committees, director expertise and education, and reporting mechanisms-and the disclosure and transparency requirements, including SEC expectations and reputational-risk management.
Under Caremark and its progeny, directors face personal liability for a sustained failure to oversee mission-critical risks-and AI is fast becoming exactly that. Boards that cannot show a functioning system to surface material AI risks are exposed, as are companies whose disclosures understate AI and cybersecurity dependence. This session shows directors and their advisors how to build oversight that satisfies the duty and withstands scrutiny.
Unlimited Viewing Recorded Version for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)